Literature DB >> 21618216

MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development.

Holger Heyn1, Maria Engelmann, Sabine Schreek, Philipp Ahrens, Ulrich Lehmann, Hans Kreipe, Brigitte Schlegelberger, Carmela Beger.   

Abstract

The expression of microRNAs is altered in various cancer types, leading to their definition as onco- and tumor-suppressor microRNAs. In our study, we investigated the role of miR-335 in the formation of sporadic human breast cancer and its involvement in the regulatory network of the breast cancer susceptibility gene BRCA1. To validate single components of the BRCA1 cascade, microRNA overexpression was performed in a cell culture model with subsequent protein analysis and luciferase reporter assays. Here, we were able to identify miR-335 as simultaneously regulating the known BRCA1 activators ERα, IGF1R, SP1 and the repressor ID4, including a feedback regulation of miR-335 expression by estrogens. Overexpression of miR-335 resulted in an upregulation of BRCA1 mRNA expression, suggesting a functional dominance of ID4 signaling. The relevance of the miR-335 regulation for human breast cancer was confirmed in primary sporadic breast cancer specimens with significantly decreased miR-335 levels (p < 0.05) in comparison to normal controls. Interestingly, the microRNA expression level correlated positively to the BRCA1 transcript level, supporting the hypothesis of a miR-335-mediated regulation of the tumor suppressor gene. Functionally, overexpression of miR-335 led to decreased cell viability and an increase in apoptosis, supporting its tumor-suppressive function. In summary, our data indicate that miR-335 affects different targets in the upstream BRCA1-regulatory cascade with impact on key cellular functions such as proliferation and apoptosis. Deregulation of the microRNA during breast cancer development and progression may thereby lead to an increased tumorigenic potential by inactivating crucial tumor-suppressive signals.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21618216     DOI: 10.1002/ijc.25962

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  62 in total

1.  MicroRNA-335 represents an independent prognostic marker in cervical cancer.

Authors:  Changhe Wang; Tao Jiang
Journal:  Tumour Biol       Date:  2015-02-25

Review 2.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

3.  MicroRNAs As Biomarkers For Clinical Features Of Lung Cancer.

Authors:  Roland Hubaux; Daiana D Becker-Santos; Katey S S Enfield; Stephen Lam; Wan L Lam; Victor D Martinez
Journal:  Metabolomics (Los Angel)       Date:  2012-03-21

Review 4.  The ID proteins: master regulators of cancer stem cells and tumour aggressiveness.

Authors:  Anna Lasorella; Robert Benezra; Antonio Iavarone
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

5.  MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance.

Authors:  Elizabeth C Martin; Adrienne K Conger; Thomas J Yan; Van T Hoang; David F B Miller; Aaron Buechlein; Douglas B Rusch; Kenneth P Nephew; Bridgette M Collins-Burow; Matthew E Burow
Journal:  FEBS Lett       Date:  2017-01-12       Impact factor: 4.124

6.  MicroRNA-335 targets the MEK/ERK pathway to regulate the proliferation and metastasis of colon cancer.

Authors:  Chuang Yang; Minghua Wang; Junde Zhou; Qiang Chi
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

7.  Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts.

Authors:  Hao Hu; Yi Zhang; Xian-Hua Cai; Ji-Feng Huang; Lin Cai
Journal:  Oncol Lett       Date:  2012-08-16       Impact factor: 2.967

Review 8.  BRCA1 and microRNAs: emerging networks and potential therapeutic targets.

Authors:  Suhwan Chang; Shyam K Sharan
Journal:  Mol Cells       Date:  2012-07-24       Impact factor: 5.034

Review 9.  Emergence of Circulating MicroRNAs in Breast Cancer as Diagnostic and Therapeutic Efficacy Biomarkers.

Authors:  Vaishali Aggarwal; Kumari Priyanka; Hardeep Singh Tuli
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.074

Review 10.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.